Biocure Technology Inc.
Biocure Technology Inc.
CSE Index:
NoCurrency:
CAD Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE.X)
(%)
*Financial charts powered by Quotemedia.com. All right reserved. View the Terms of Use. Data delayed 15 minutes unless indicated.
Company Info
Address
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaPhone
604-609-7146Email
admin@biocuretech.comWebsite
http://www.biocuretech.comListing date
Monday, May 10, 2010Transfer Agent
Computershare Investor Services Inc.Investor Relations
Purple Crown Communications Corp.Email
Julie@purplecrown.caAuditor
DMCL Chartered Professional AccountantsSEDAR Information
Filing Type
Any
Timeframe
1 week1 month3 month6 month1 yearAll Time
Company Info
Address
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaPhone
604-609-7146Email
admin@biocuretech.comWebsite
http://www.biocuretech.comListing date
Monday, May 10, 2010Transfer Agent
Computershare Investor Services Inc.Investor Relations
Purple Crown Communications Corp.Email
Julie@purplecrown.caAuditor
DMCL Chartered Professional AccountantsCapitalization
Issued & Outstanding:
10444504Reserved for Issuance:
884059Company Officers
Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer
News Releases
Bulletins
23/10/2024
2024-1024 – Consolidation - Biocure Technology Inc. (CURE.X)
le 23 octobre/October 2024
Biocure Technology Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every nine (9) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 10,444,504 common shares.
The name and symbol will not change.
